Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
NCT02558387
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck
Interventions
DRUG:
BIBF1120
Sponsor
Samsung Medical Center